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Abstract. Bladder cancers are usually curable, by surgical 
or transurethral excision, if diagnosed at an early stage. 
Tumor derived mutations in oncogenes potentially provide 
specific markers for the detection of surgically resectable 
tumors. The detection of point mutations of Η-ras oncogene 
correlated with this disease. DNA sequences produced by 
the Polymerase Chain Reaction (PCR) can be considered 
for this application, because theoretically bladder tumors 
should shed cells containing this mutation into the urine. 
We examined urine from 21 individuals with bladder cancer 
before any treatment, as well as tissue specimens from the 
excised tumor and we found 10 mutations of the Η-ras gene 
at codon 12 in the urine (47.61%) and 14 mutations in the 
tumor specimens (66.66%). We were able to detect nearly 
50% of the patients with bladder tumors using this method. 
We also studied two relapses; in one case (which presented 
the mutation in the original tumor and the urine) the relapse 
grade had progressed from II to III. In the other case the 
relapse grade stayed at III but it presented for the first time 
the studied mutation in the urine. These results provide the 
theoretical and technical basis for the detection of bladder 
tumors by a non-invasive method and possibly for the 
evaluation of the invasiveness of the disease. 
Introduction 
Bladder cancer is a common malignancy in the world with 
180,000 new cases expected in 1992. Whereas individuals 
with advanced disease have a poor prognosis, bladder 
tumors diagnosed in an earlier stage can usually be cured 
with transurethral or surgical excision. Only 10 to 15% of 
patients with superficial bladder cancer subsequently 
develop invasive or metastatic disease (1,2), however, 
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approximately 70% of patients have one or more tumor 
recurrences (3), which express a higher histologic grade in 
about 25% of cases. Methods to detect surgically resectable 
tumors could therefore reduce deaths from the disease. 
Tumor derived mutations in oncogenes potentially provide 
specific markers for such a detection. 
Oncogenes are highly conserved genes in any living 
organism and have important functions in cellular 
proliferation and differentiation. Loss of regulation in this 
complex system, resulting from structural modification of a 
normal gene or of its controlling regions, is called oncogene 
activation. A family of such genes that is frequently found to 
harbour a mutation in human tumors is that of ras genes (4). 
This family consists of three functional genes: Η-ras, K-ras 
and N-ras, which encode highly similar proteins with 
molecular weights of 21,000. Mutated ras genes were first 
identified by their ability to transform NIH/3T3 cells after 
DNA transfection. Subsequent analysis of a variety of tumor 
samples revealed that some human tumors had one of the 
three ras genes harbouring a point mutation; as a result, the 
protein produced has an altered amino acid residue at one of 
the critical positions 12, 13 or 61. 
Η-ras oncogene activations are known to occur during the 
process of bladder carcinogenesis in humans, along with the 
tumor progression. In vitro experiments have shown that the 
transfection of the Η-ras oncogene into a low metastatic 
epithelial cell line results in the acquirement of significantly 
increased metastatic capacity (5) and also that the malignant 
properties of cellular sublines selected from a human bladder 
cancer cell line which contains an activated Η-ras oncogene 
are highly enhanced (6). Other experiments have proved the 
activation of this oncogene in rat bladder tumors induced by 
the N-butyl-N-(4-hydroxybutyl)nitrosamine (7). However, no 
specific correlation has been demonstrated that was relevant 
to this process, until the detection of point mutations in total 
genomic DNA became feasible. 
Experiments based on the NIH/3T3 cell transfection assay 
found an increased number of Η-ras codon 12 mutations 
among the samples of patients with bladder cancer (8-10). 
This frequency ranged from 0 to 17% but the overall 
frequency of Η-ras point mutations has probably been 
underestimated by these techniques. 
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Η-ras oncogene sequence with wild type codon 12 
Τ 
5 ' . . GAGACCCTGTAGGAGGACCCCGG GGCGCCGGCGGT AGTCCCTCGTCTCAGCACCC.. 3 ' 
5" GAGACCCTGTAGGAGGACCC 3' 3'TCAGGGAGCAGAGTCGTGGG 5' 
H5 (H-ras 1620-1640) primers H3 (H-ras 1912-1932) 
• PCR amplification 
5 ' GAGACCCTGTAGGAGGACCCCGG GGCGCCGGCGGT AGTCCCTCGTCTCAGCACCC 3 ' 
PCR product (312bp) 
• Msp I digestion 
5 ' GAGACCCTGTAGGAGGACCC 3 ' 5 ' CGG GGCGC 3 ' 5'CGGCGGT AGTCCCTCGTCTCAGCACCC 3 ' 
21bp 55bp 236bp 
Digestion's products 
CCGG = Msp I restriction site 
Figure 1. H-ra.v sequence and related primers. 
The Polymerase Chain Reaction (PCR) is an in vitro 
method for the primer directed enzymatic amplification of 
specific DNA sequences. This technique allows the detection 
of point mutat ions in genes already sequenced with a 
sensitivity of 5% to 10% i.e. cells carrying a mutation can be 
detected, among a population of non-carrying cells, if they 
represent at least 5% of the total cell population. 
However, tumors are composed of heterogeneous cell 
populations (neoplastic cells, infiltrated inflammatory cells, 
normal t issue cel l s) . This heterogenei ty increases the 
background 'noise' elevating the number of amplified non-
mutated sequences and thus decreases the sensitivity of the 
detection. Therefore, it is often important to detect point 
mutations at this level of sensitivity in many samples of the 
same patient, especially after a treatment, in order to evaluate 
the efficiency of the therapeutic action and the level (if any) 
of the residual disease. The detection of a point mutation in 
the adjacent apparently 'normal' tissue provides a prognostic 
marker, relevant to the identification or the prevention of 
further tumor progress ion. These factors are of great 
importance in the understanding of the commitment of cells 
to neoplasia and malignancy. 
The detection of point mutations at codon 12 of the H-ras 
oncogene into the enzymatically amplified DNA sequences, 
was per formed by d iges t ion of PCR products s ince a 
restriction site for the endonuclease Msp I exists in the wild 
type (non-mutated) form of the amplified sequence (11) but 
not in any mutated version. A second restriction site for Msp I 
was artificially introduced by the first primer in all amplified 
sequences (wild type and mutated) in order to be used as a 
control for the d iges t ion (Fig. 1). This p e r m i t t e d the 
elimination of all incomplete digestion which could be falsely 
interpreted as mutated samples. The PCR amplifies a 312bp 
region of the H-ras gene, which is digested by Msp I and 
analysed on a 4% agarose gel. This sensitive method, 
connected with the feasibility of PCR amplification of DNA 
in cells seeded by the tumors into the urine, prompted us to 
evaluate the frequency of H-ras point mutations at codon 12 
in bladder carcinomas. 
Theoretically, bladder tumors should shed cells containing 
the H-ras codon 12 mutation into the urine. However, urine is 
a complex mixture consisting of various soluble and insoluble 
products, mucus, microorganisms, and contains numerous 
degradative enzymes derived from cells and bacteria. It was 
therefore unclear whether mutant genes from tumor cells 
could be detected in clinical specimens. In this study we have 
shown that H-ras mutations can be detected in the urine of 
patients with bladder tumors. 
Materials and methods 
Clinical specimens. Tumors , normal mucosa and urine 
samples were obtained from patients who underwent surgery 
in the Urological Clinic at Tzannion General Hospital of 
P i reas . Urine samples were taken one day before the 
operation. 
DNA extraction. Tumor and mucosa samples were put 
directly into 300 μΐ lysis solution containing 0.2N NaOH/ 
2M NaCl. Urine samples were centrifuged at 1,500 rpm for 
10 min, the supernatant was removed and 10 μΐ of the 
concentrated cell pellet was added to the lysis solution. 
All samples were boiled for 5 min and subsequently 
centrifuged for another 5 min. Supernatants were transferred 
to fresh tubes and 1 ml of ethanol was added. Tubes were 
s tored at -20°C o v e r n i g h t . D N A was r e c o v e r e d by 
centrifugation for 15 min at 4°C, washed twice with 70% 
ethanol and resuspended in 20 μΐ distilled water. 
Oligonucleotides and PCR amplification. The 
oligonucleotides (H5 and H3) used as primers for the PCR 
amplification of the region of the H-ras oncogene which 
includes codon 12, have been previously described (11) and 
are schematically presented in Fig. 1 along with the H-ras 
sequence. We also used oligos especially designed for the 
detection of the K-ras 12 mutations (12). 
1 μΐ of DNA extract was amplified in a volume of 100 μΐ 
containing 10 mM Tris-HCl pH 8.3 / 50 mM KCl /l mM 
MgCK 200 mM dNTPs, 50 ng of each primer and 2.5 U of 
Taq polymerase. Amplification was performed in a Perkin 
Elmer Cetus Thermal Cycler using the following conditions: 
denaturation 1 min at 95"C, primer annealing and extension 1 
min at 68"C for 35 consecutive cycles. 
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Figure 2. PCR products electrophoresis: 5-20 μΙ of PCR products were 
digested with Mspl and the digestion products were electrophoresed in a 
agarose gel. Lane A: pUCI8 / Hae III molecular weight marker. Lane B: 
undigested PCR product. Lane C: negative sample. Lane D: positive control 
(2 mutated alleles). Lane E: positive sample. 
Table I. Detection of H-ra.v codon 12 mutations in 21 patients 

































































T, N 0 M 0 
T , N 0 M 0 
T , N 0 M 0 
T , N 0 M 0 
T , N 0 M 0 
T , N 0 M 0 
T, N ( ) M ( ) 
T 2 N 0 M 0 
T, N 0 M„ 
T
:
 N 0 M„ 
T, N 0 M 0 
T, N 0 M 0 
T, N 0 M 0 
T, N 0 M 0 
T , N 0 M 0 
T2 N 0 Mo 
T , N 0 M 0 
T 2 N 0 M 0 
T 2 N 0 M 0 
T , N 0 M 0 
T, N 0 M 0 





















Restriction enzyme analysis. 5-20 μΐ of PCR products were 
digested with Mspl at 37"C in the conditions recommended 
by the manufacturer of the enzyme. Digestion products were 
electrophoresed in a 4% LMP agarose gel containing 0.5% 
ethidium bromide. Gels were photographed on a UV light 
transilluminator. 
Results and Discussion 
We examined urine from 21 individuals with bladder cancer 
before any treatment, and tissue specimens from their excised 
tumor and the adjacent normal mucosa. A representative 
photograph of PCR products electrophoresis is shown in Fig. 2. 
We found 10 mutations of the H-ras gene at codon 12 in 
the urine (47.61%), 14 mutations in the tumor specimens 
(66.66r/r ) but no mutations were found in normal mucosa, as 
expected. These results together with patient's age, therapy, 
tumor primary grade and stage are presented in Table I. Fig. 
3 shows a graphical representation of our findings 
concerning H-ra.v codon 12 mutation in bladder tumors. As 
shown, we can detect nearly 50% of the patients with bladder 
tumors using this method, which is based on the molecular 
pathogenesis of the disease. 
The elevated frequency of the detection of mutated H-ra.v 
oncogene in the urine can be explained by the fact that 
bladder tumors contribute a significant fraction of the human 
DNA present in the urine as their cells turn over at an 
with bladder tumors. 
ras mutations detected in 
Complementary therapy 
urine tumor mucosa 
epirubicin (topical) 















































aTURT = transurethral resection treatment. 
734 HALIASSOS et al: Η-ras MUTATIONS IN BLADDER TUMORS 
Π non-mutated 
Mutated at Η-rascodon 12 
• detected in urine 
• non-detected in urine 
Figure 3. Η-ras codon 12 mutations in bladder tumors. 
elevated rate compared to normal cells and by the high 
sens i t iv i ty of the d e t e c t i o n m e t h o d . S imi lar resul t s 
concerning the detection of mutated K-ras oncogene in the 
stool of patients with curable colorectal tumors have been 
reported recently (13). No mutations of the codon 12 in the 
K-ras oncogene were found in the tumors of our 21 patients 
with bladder carc inomas in accordance with previous 
findings (10). 
We also studied two relapses of the patients 14 and 15. In 
patient 14 (which presented the mutation in the original 
tumor and the urine) the relapse grade had progressed from II 
to III and was also positive for this H-ra.v codon 12 mutation. 
The relapse grade for patient 15 was III and it presented for 
the first time the studied mutation in the urine. 
Investigation into ras and other oncogenes and additional 
studies in which the urine from a large number of patients 
with bladder tumors of varying size, stage and relapse are 
studied, will be needed to determine more accurately the 
correlations between the detection of the mutated H-ras 
oncogenes and the invasiveness of the tumors. 
These results provide the theoretical and technical basis 
for the detection of bladder.tumors with a non-invasive 
method. This could eventually be used in the screening of 
a s y m p t o m a t i c p a t i e n t s e spec ia l ly those at risk from 
environmental factors for the presence of bladder neoplasia 
as well as possibly in other tumors such as head and neck, 
stomach, kidney, prostate, etc by appropriate adaptation of 
this technique to search for mutated DNA in urine or other 
biological fluids or excretions. 
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